FILE PHOTO: Chinese fax manufacturer CanSino Biologics’ sign is pictured at its building in Tianjin, China November 20, 2018. Image taken November 20, 2018. REUTERS / Stringer
BEIJING (Reuters) – Chinese vaccine specialist CanSino Biologics Inc has won a patent judgment from Beijing for its COVID-19 vaccine candidate Ad5-nCOV, state media reported, citing documents from the country’s intellectual property regulator.
It is the first COVID-19 vaccine patent to be granted by China, state newspaper People’s Daily reported on Sunday.
The paper cited documents published by China’s National Intellectual Property Administration that said the patent was issued on August 11.
Saudi Arabia said this month that it plans to launch Phase III clinical trials for the CanSino vaccine. CanSino has said it is also in talks with Russia, Brazil and Chile to launch Phase III trials in those countries.
CanSino’s shares in Hong Kong rose around 14% in Monday morning’s session. Shares in Shanghai rose 6.6% at noon.
Report by Sophie Yu and Brenda Goh; Edited by Tom Hogue
.
